Domača stranBNTX • NASDAQ
add
BioNTech
97,47 $
Pred odprtjem:(1,20 %)+1,17
98,63 $
Konec trgovanja: 14. mar., 05:40:57 GMT -4 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
100,31 $
Dnevni razpon
97,41 $ - 104,17 $
Letni razpon
76,53 $ - 131,49 $
Tržna kapitalizacija
23,37 mrd. USD
Povprečni obseg
842,79 tis.
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (EUR) | dec. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 1,19 mrd. | −19,54 % |
Stroški poslovanja | 816,80 mio. | 15,68 % |
Čisti dohodek | 259,50 mio. | −43,33 % |
Čista dobičkovnost prihodkov | 21,81 | −29,55 % |
Earnings per share | 1,08 | −43,16 % |
EBITDA | 295,10 mio. | −52,96 % |
Efektivna davčna stopnja | 13,84 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (EUR) | dec. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 16,78 mrd. | 1,42 % |
Skupna sredstva | 22,53 mrd. | −2,07 % |
Skupne obveznosti | 3,12 mrd. | 12,98 % |
Celoten lastniški kapital | 19,41 mrd. | — |
Shares outstanding | 240,28 mio. | — |
Razmerje P/B | 1,24 | — |
Donosnost sredstev | 1,44 % | — |
Donosnost kapitala | 1,66 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (EUR) | dec. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 259,50 mio. | −43,33 % |
Denar iz dejavnosti | −463,30 mio. | −154,45 % |
Denar iz naložb | 606,70 mio. | 122,51 % |
Denar iz financiranja | −7,30 mio. | 43,41 % |
Neto sprememba denarnih sredstev | 137,30 mio. | 107,49 % |
Prost denarni tok | −174,31 mio. | −130,65 % |
Vizitka
BioNTech SE is a global biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Generalni direktor
Datum ustanovitve
2008
Spletno mesto
Zaposleni
6.772
